Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Êàðäèîëîãèÿ > Ôîðóì äëÿ îáùåíèÿ âðà÷åé êàðäèîëîãîâ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #106  
Ñòàðûé 30.09.2009, 22:42
Àâàòàð äëÿ Gilarov
Gilarov Gilarov âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,196
Ïîáëàãîäàðèëè 713 ðàç(à) çà 691 ñîîáùåíèé
Gilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò rodrn Ïîñìîòðåòü ñîîáùåíèå
Âû çíàåòå õîòÿ áû îäíîãî îáùåãî òåðàïåâòà èëè êàðäèîëîãà, êîòîðûé èçìåðÿë áû toe blood pressure è transcutaneous oxygen tension (TcPO2)?
Ðîìàí, à íàñêîëüêî ìíå, êàðäèîëîãó, íàäî ýòî çíàòü? Äî ñåãîäíÿøíåãî äíÿ ÿ ýòîãî íå çíàë è áûë ñ÷àñòëèâ â ñâîåì íåâåäåíèè. Íî åñëè íàäî, ÿ îñâîþ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #107  
Ñòàðûé 30.09.2009, 23:01
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,960
Ïîáëàãîäàðèëè 33,497 ðàç(à) çà 31,833 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âîïðîñ ìîæåò ñòîÿòü è ïî äðóãîìó: ïðåæäå ÷åì ó÷èòüñÿ ìåðÿòü ãåìîäèíàìè÷åñêèå ïàðàìåòðû ó âñåõ ïàöèåíòîâ ñ PAD, áûòü ìîæåò ðàçîáðàòüñÿ, íåñóò ëè îíè äîï. ïðîãíîñòè÷åñêóþ èíôîðìàöèþ ó íèõ? Íàïð. â ñâåòå òàêîé ïóáëèêàöèè:

Vasc Med. 2006 Nov;11(3):155-63.
Limb hemodynamics are not predictive of functional capacity in patients with PAD.
Szuba A, Oka RK, Harada R, Cooke JP.
Division of Cardiovascular Medicine, 300 Pasteur Drive, Stanford University School of Medicine, Stanford, CA 94305, USA.

To the practicing clinician, it seems obvious that limb hemodynamics would be the primary determinant of walking distance. However, other determinants, such as skeletal muscle metabolism, may play a role. Accordingly, in the current study, we examined the relationship between measures of limb hemodynamics and walking capacity in patients with peripheral arterial disease (PAD). We measured toe and ankle pressures for calculation of toe- (TBI) and ankle (ABI)-brachial indices; basal and hyperemic calf blood flow (CBF; by plethysmography); and initial (ICT) and absolute (ACT) claudication time using the Skinner-Gardner protocol. As expected, PAD patients had impaired limb hemodynamics with reduced TBI, ABI and a reduction in ABI post-exercise. However, there was no relationship between any of the hemodynamic variables (including ABI, ABI reduction post-exercise, TBI, baseline or maximal CBF) and walking distance as assessed by ICT or ACT. A subset of PAD patients with an ACT >750s (n = 16; 'long claudicators') were compared with a subset of PAD patients with an ACT <260s (n = 16; 'short claudicators'). The average ACT in the long claudicants was over fivefold greater than the short claudicators. Surprisingly, there were no differences between the two groups in any of the hemodynamic variables. There was also no relationship between the initial ABI, TBI, toe pressure, baseline or hyperemic CBF, and the improvement in ACT over the 3-month course of the study. This study found little relationship between hemodynamic variables and functional capacity in PAD. Accordingly, to assess the response to therapeutic interventions, exercise performance and functional status need to be directly measured, and cannot be predicted from hemodynamic measurements.
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #108  
Ñòàðûé 30.09.2009, 23:13
acha acha âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 04.04.2006
Ãîðîä: Ðîññèÿ
Ñîîáùåíèé: 3,714
Ñêàçàë(à) ñïàñèáî: 2
Ïîáëàãîäàðèëè 237 ðàç(à) çà 233 ñîîáùåíèé
acha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ÿ ñòåñíÿþñü ñïðîñèòü, ÷òî êðîìå

àñïèðèíà
ïëàâèêñà
òðåíòàëà
ñòàòèíîâ
öèëîñòàçîëà (íó åòî íå äëÿ íàñ)
ëå÷åíèÿ ñîïóòñòâóþùåé ïàòîëîãèè
õèðóðãèè

ïîÿâèëîñü â ëå÷åíèè àòåðîñêëåðîòè÷åñêîãî ïîðàæåíèÿ çàäíèõ êîíå÷íîñòåé?

ýòî ÿ ê ÷åìó: à êàêèå çàäà÷è áóäóò ñòàâèòüñÿ ïåðåä àíãèîòåðàïåâòìè?

Êîììåíòàðèè ê ñîîáùåíèþ:
dav1972 îäîáðèë(à): À òðåíòàë ðàçâå íå âûêèäûâàåì èç ýòîãî áëàãîðîäíîãî íàáîðà?
Iluhin îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #109  
Ñòàðûé 30.09.2009, 23:38
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,960
Ïîáëàãîäàðèëè 33,497 ðàç(à) çà 31,833 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Åøå è ïðèëû:

Peripheral artery disease: potential role of ACE-inhibitor therapy

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #110  
Ñòàðûé 01.10.2009, 07:58
rodrn rodrn âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 24.08.2009
Ãîðîä: Dresden
Ñîîáùåíèé: 295
Ñêàçàë(à) ñïàñèáî: 36
Ïîáëàãîäàðèëè 10 ðàç(à) çà 10 ñîîáùåíèé
rodrn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìårodrn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Gilarov Ïîñìîòðåòü ñîîáùåíèå
Ðîìàí, à íàñêîëüêî ìíå, êàðäèîëîãó, íàäî ýòî çíàòü? Äî ñåãîäíÿøíåãî äíÿ ÿ ýòîãî íå çíàë è áûë ñ÷àñòëèâ â ñâîåì íåâåäåíèè. Íî åñëè íàäî, ÿ îñâîþ.
Êàê êàðäèîëîãó ñîâåðøåííî íåò íåîáõîäèìîñòè. À âîò åñëè Âû ðåøèòå çàíÿòüñÿ ðóòèííûì êîíòðîëåì ïàöèåíòîâ ñ PAD, òî çíàòü íàäî îáÿçàòåëüíî. Ìû óæå îáñóæäàëè âûøå, ïî÷åìó ýòè ìåòîäû íåîáõîäèìû äëÿ îöåíêè ïðîãðåññèè çàáîëåâàíèÿ.  ïðîòèâíîì ñëó÷àå ðóòèííûå êîíòðîëè ïðèäåòñÿ ïðîâîäèòü õèðóðãàì, à ýòî òðàòà èõ äðàãîöåííîãî õèðóðãè÷åñêîãî âðåìåíè (Âû æå íå îæèäàåòå, ÷òî, íàïðèìåð, êàðäèîõèðóðãè áóäóò çàíèìàòüñÿ ðóòèííûìè êîíòðîëÿìè?) è, ÷òî ðåëåâàíòíåå äëÿ äàííîãî îáñóæäåíèÿ, âåäåò ê íåäîñòàòî÷íî õîðîøî ïîäîáðàííîé ìåäèêàìåíòîçíîé òåðàïèè.

Ðèñêíó ïðåäïîëîæèòü, ÷òî äëÿ êàðäèîëîãîâ çàíèìàòüñÿ àäåêâàòíûìè (ñ ïîëíîé äèàãíîñòèêîé) ðóòèííûìè êîíòðîëÿìè ïàöèåíòîâ ñ PAD ïðåäñòàâëÿåòñÿ/ÿâëÿåòñÿ íåïðîñòèòåëüíîé òðàòîé ñèë è âðåìåíè (ñâîèõ ïàöèåíòîâ õâàòàåò). Ïîýòîìó íåìöû è ïîøëè ïî ïóòè ñîçäàíèÿ îòäåëüíîé òåðàïåâòè÷åñêîé ñïåöèàëèçàöèè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #111  
Ñòàðûé 01.10.2009, 08:19
KMN KMN âíå ôîðóìà ÂÐÀ×
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 16.02.2007
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 588
Ïîáëàãîäàðèëè 27 ðàç(à) çà 26 ñîîáùåíèé
KMN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKMN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKMN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKMN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKMN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKMN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKMN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKMN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKMN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKMN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò rodrn Ïîñìîòðåòü ñîîáùåíèå
Âîïðîñ, ÿ òàê ïîíèìàþ, ðèòîðè÷åñêèé. Ðàçâåéòå òîãäà, ïîæàëóéñòà, Âàøó ìûñëü äî êîíöà.
Íè÷åãî ðèòîðè÷åñêîãî, ìûñëü ðàçîâüåòñÿ ïî ìåðå Âàøèõ îòâåòîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #112  
Ñòàðûé 01.10.2009, 10:44
Àâàòàð äëÿ Gilarov
Gilarov Gilarov âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,196
Ïîáëàãîäàðèëè 713 ðàç(à) çà 691 ñîîáùåíèé
Gilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Ðîìàí!
×òî ðóññêîìó çäîðîâî, òî íåìöó ñìåðòü. Ïîêà ïåðåäîâîé ãåðìàíñêèé ìåòîä íå ñïåøàò âíåäðèòü, ñêàæåì, â ÑØÀ. Ïîäîæäåì, íàâåðíîå, è ìû, ïîêà äðóãèõ ïðîáëåì õâàòàåò. Íî ìû îòêðûòû äëÿ ïðåäëîæåíèé. Âîçâðàùàéòåñü è îñíîâûâàéòå íîâóþ øêîëó.
Îòâåòèòü ñ öèòèðîâàíèåì
  #113  
Ñòàðûé 01.10.2009, 11:32
rodrn rodrn âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 24.08.2009
Ãîðîä: Dresden
Ñîîáùåíèé: 295
Ñêàçàë(à) ñïàñèáî: 36
Ïîáëàãîäàðèëè 10 ðàç(à) çà 10 ñîîáùåíèé
rodrn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìårodrn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Òàê íå îáÿçàòåëüíî æå íåìåöêîå ðåøåíèå âîïðîñà. ß âûøå ïèñàë, ÷òî, ÈÌÕÎ, ðåøåíèå çàâèñèò îò êîíêðåòíîé ìåäèöèíñêîé ñèñòåìû, ãëàâíîå îáåñïå÷èòü àäåêâàòíóþ òåðàïåâòè÷åñêóþ è äèàãíîñòè÷åñêóþ ïîääåðæêó. Òî, ÷òî PAD íåäîîöåíèâàþò, óòâåðæäàþò è àìåðèêàíöû (ñì. ìíîãî÷èñëåííûå ññûëêè îò Dr. Vad'a).
Âàðèàíò ñ àíãèîëîãèåé óäîáåí òåì, ÷òî íà àíãèîëîãîâ ìîæíî ñáðîñèòü âñþ ñîñóäèñòóþ äèàãíîñòèêó (ìû íå ãîâîðèëè åùå â ýòîé âåòêå î òðîìáîçå ãëóáîêèõ âåí, ïîñòòðîìáîòè÷åñêîì ñèíäðîìå, âàðèêîçàõ; ñìåøàííûå àðòåðèîâåíîçíûå ïîðàæåíèÿ - îòäåëüíûé âîïðîñ; äèàãíîñòèêà ýìáîëèé; ïîðàæåíèÿ âåðõíèõ êîíå÷íîñòåé (íàïðèìåð, thoracic outlet syndrom), ñîñóäèñòàÿ äèàãíîñòèêà ïðè âàñêóëèòàõ è ò.ä.). Íåäîñòàòîê òîæå î÷åâèäåí: ñîçäàíèå íîâîé ñïåöèàëüíîñòè òðåáóåò çàòðàòû ðåñóðñîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #114  
Ñòàðûé 01.10.2009, 11:33
rodrn rodrn âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 24.08.2009
Ãîðîä: Dresden
Ñîîáùåíèé: 295
Ñêàçàë(à) ñïàñèáî: 36
Ïîáëàãîäàðèëè 10 ðàç(à) çà 10 ñîîáùåíèé
rodrn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìårodrn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò KMN Ïîñìîòðåòü ñîîáùåíèå
Íè÷åãî ðèòîðè÷åñêîãî, ìûñëü ðàçîâüåòñÿ ïî ìåðå Âàøèõ îòâåòîâ.
Òî÷íûé îòâåò íå çíàþ, íî ïðîäïîëàãàþ, ÷òî cardiovascular disease, êàê è â îñòàëüíûõ ðàçâèòûõ ñòðàíàõ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #115  
Ñòàðûé 01.10.2009, 18:29
rodrn rodrn âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 24.08.2009
Ãîðîä: Dresden
Ñîîáùåíèé: 295
Ñêàçàë(à) ñïàñèáî: 36
Ïîáëàãîäàðèëè 10 ðàç(à) çà 10 ñîîáùåíèé
rodrn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìårodrn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò acha Ïîñìîòðåòü ñîîáùåíèå
ýòî ÿ ê ÷åìó: à êàêèå çàäà÷è áóäóò ñòàâèòüñÿ ïåðåä àíãèîòåðàïåâòìè?
Ïðî òðåíòàë ïîïðîøó ññûëêó. Äîáàâèì ïðîñòàâàçèí, ïðèëû, ôèáðèíîëèç, âàðôàðèí, íàôòèäðîôóðèë. Ïîòîì äîáàâèì íåàòåðîñêëåðîòè÷åñêèå ïîðàæåíèÿ àðòåðèé, ïîòîì çàáîëåâàíèÿ âåíîçíîé è ëèìôàòè÷åñêèõ ñèñòåì. À ïîñëå ýòîãî äîáàâèì âñå íåîáõîäèìûå äèàãíîñòè÷åñêèå ìåòîäû, ÷òî â íåñêîëüêî ðàç óâåëè÷èò îáúåì ðàáîòû. Èíòåðâåíöèè â áîëüøèíñòâå ñòðàí òîæå, êñòàòè, âûïîëíÿþò òåðàïåâòû (íî ýòî óæå äîïîëíèòåëüíàÿ ïðîãðàììà)
Îòâåòèòü ñ öèòèðîâàíèåì
  #116  
Ñòàðûé 01.10.2009, 19:50
Àâàòàð äëÿ oldangio
oldangio oldangio âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 28.06.2009
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 952
Ñêàçàë(à) ñïàñèáî: 11
Ïîáëàãîäàðèëè 75 ðàç(à) çà 70 ñîîáùåíèé
oldangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåoldangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåoldangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåoldangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåoldangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåoldangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåoldangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåoldangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ìèõàèë Þðüåâè÷! Ñìîòðèòå øèðå, ðàíüøå âñå áîëåçíè áûëè îò íåðâîâ, à ñåé÷àñ áîëåçíè îò ïîðàæåíèÿ ñîñóäèñòîé ñèñòåìû(àðòåðèè, âåíû è ëèìôàòè÷åñêèå ñîñóäû). Êòî ëó÷øå âñåõ òåðàïåâòîâ - ýòî êàðäèîëîãè.  ñâåòå ïîñëåäíèõ èçìåíåíèé è ïîÿâëåíèÿ íîâûõ ñïåöèàëüíîñòåé è ïî àíàëîãèè ñ ñåðäå÷íî-ñîñóäèñòîé õèðóðãèåé ïðåäëàãàþ íàçûâàòü êàðäèîëîãîâ ïî íîâîìó "êàðäèîàíãèîëîãàìè". òîãäà â èõ ñâåòëûõ ãîëîâàõ è ñèëüíûõ ðóêàõ îáúåäèíèòñÿ âñÿ äèàãíîñòèêà è ëå÷åíèå ïðàêòè÷åñêè âñåõ ïàöèåíòîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #117  
Ñòàðûé 01.10.2009, 19:58
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,960
Ïîáëàãîäàðèëè 33,497 ðàç(à) çà 31,833 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò rodrn Ïîñìîòðåòü ñîîáùåíèå
Ïðî òðåíòàë ïîïðîøó ññûëêó.
Can Med Assoc J 1996;155,1053-1059.

Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials
S. C. Hood, D. Moher and G. G. Barber
Health Analysis and Modelling Group, Social and Economic Studies Division, Statistics Canada, Ottawa, Ont.

OBJECTIVE: To evaluate the efficacy of pentoxifylline therapy in improving the walking capacity of patients with moderate intermittent claudication. DATA SOURCES: A search of MEDLINE for trials published between 1976 and 1994 inclusive, and a bibliographic review of all articles retrieved. STUDY SELECTION: Randomized, placebo-controlled, double-blind clinical trials were selected that evaluated the pain-free walking distance (the distanced walked on a treadmill before the onset of calf pain) and the absolute claudication distance (the maximum distance walked on a treadmill) among patients with moderate intermittent claudication. Twelve study groups in 11 trials were included in the analysis. DATA EXTRACTION: In addition to information regarding the trial design, patient characteristics, dosages and treatment periods, the means and standard deviations were collected for both the pain-free walking and absolute claudication distances. Trial quality was also assessed. DATA SYNTHESIS: Overall, there was a statistically significant improvement in the pain-free walking distance after pentoxifylline therapy (weighted mean difference 29.4 m [95% confidence interval (CI) 13.0 to 45.9 m]); this finding was based on a total sample of 612 patients (308 in the treatment groups and 304 in the control groups). A significant improvement was also noted in the absolute claudication distance (weighted mean difference 48.4 m [95% CI 18.3 to 78.6 m]); this was based on a total sample of 511 patients (258 in the treatment group and 253 in the control group). In a sensitivity analysis of the pain-free walking distance, significant treatment effects and no statistically significant heterogeneity were found when only trials were included that were "medically eligible" (involved patients with stage II disease and a pain-free walking distance of 50 to 200 m). In a similar sensitivity analysis of the absolute claudication distance, the two conditions resulting in a significant treatment effect and no significant heterogeneity were the inclusion of "medically eligible" trials and those with a shorter treatment duration (13 weeks or less). CONCLUSION: Pentoxifylline therapy may be efficacious in improving the walking capacity of patients with moderate intermittent claudication. However, properly conducted clinical trials are required to provide a true estimate of the benefit.

Êîììåíòàðèè ê ñîîáùåíèþ:
acha îäîáðèë(à):
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #118  
Ñòàðûé 01.10.2009, 21:54
acha acha âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 04.04.2006
Ãîðîä: Ðîññèÿ
Ñîîáùåíèé: 3,714
Ñêàçàë(à) ñïàñèáî: 2
Ïîáëàãîäàðèëè 237 ðàç(à) çà 233 ñîîáùåíèé
acha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåacha ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò rodrn Ïîñìîòðåòü ñîîáùåíèå
Ïðî òðåíòàë ïîïðîøó ññûëêó. Äîáàâèì ïðîñòàâàçèí, ïðèëû, ôèáðèíîëèç, âàðôàðèí, íàôòèäðîôóðèë. Ïîòîì äîáàâèì íåàòåðîñêëåðîòè÷åñêèå ïîðàæåíèÿ àðòåðèé, ïîòîì çàáîëåâàíèÿ âåíîçíîé è ëèìôàòè÷åñêèõ ñèñòåì. À ïîñëå ýòîãî äîáàâèì âñå íåîáõîäèìûå äèàãíîñòè÷åñêèå ìåòîäû, ÷òî â íåñêîëüêî ðàç óâåëè÷èò îáúåì ðàáîòû. Èíòåðâåíöèè â áîëüøèíñòâå ñòðàí òîæå, êñòàòè, âûïîëíÿþò òåðàïåâòû (íî ýòî óæå äîïîëíèòåëüíàÿ ïðîãðàììà)
óâàæàåìûé DrVad ìåíÿ îïåðåäèë. òðåíòàë ìíîãî ãäå óïîìèíàåòñÿ, â òîì ÷èñëå è íà åìåäåñèí, íå òî ÷òî áû ÿ î÷åíü ëþáèë ýòîò ïðåïàðàò, ïðîñòî óïîìÿíóë âñå ÷òî êàñàåòñÿ PAD õîòü êàêèì òî áîêîì.
íî ìíå êàæåòñÿ ÿ íà÷èíàþ ïîíèìàòü âñå ãëóáèíó âçàèìíîãî íåïîíèìàíèÿ â åòîé òåìå (çàïàòåíòîâàòü ôðàçó ÷òî ëè?). Ïî-ìîåìó åòî íåäîïîíèìàíèÿ ðåçóëüòàò îòðûâà êîëëåãè rodrn îò íàøèõ ðåàëèé.
1. ó íàñ äèàãíîñòèêó ïðîâîäÿò ôóíêöèîíàëüíûå äèàãíîñòû, ò.å. íàãðóçèòå âû íå àíãèîòåðàïåâòîâ à èìåííî ôóíêöèîíàëèñòîâ.
2. òåïåðü ìåíÿ ìó÷àåò ìûñëü, êòî ïðèìåíèò ê Âàì ìåòîäû íåçàêîííîãî ôèçè÷åñêîãî âîçäåéñòâèÿ çà ìûñëü
Öèòàòà:
Èíòåðâåíöèè â áîëüøèíñòâå ñòðàí òîæå, êñòàòè, âûïîëíÿþò òåðàïåâòû
ðåíòãåíõèðóðãè èëè òåðàïåâòû, èëè åòî áóäåò òîò ðåäêèé ñëó÷àé êîãäà îíè ñêîîïåðèðóþòñÿ

íå çíàþ êàê â ñòîëèöàõ, íî ó íàñ â ãëóáèíêå áîþñü ñàìè ñîñóäèñòûå õèðóðãè áóäóò ïðîòèâ ìûñëè ëèøèòü èõ êîíñåðâàíòîâ, ïîòîìó êàê òåõíè÷åñêîå îáåñïå÷åíèå íå ïîçâîëÿåò äåëàòü íå÷òî êðóòîå, ïîòîìó äàííàÿ êàòåãîðèÿ ïàöèåíòîâ èõ õëåá íàñóùíûé
Îòâåòèòü ñ öèòèðîâàíèåì
  #119  
Ñòàðûé 01.10.2009, 22:01
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,960
Ïîáëàãîäàðèëè 33,497 ðàç(à) çà 31,833 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Õî÷åòñÿ äîáàâèòü ïî òðåíòàëó: â ñâåòå òîãî, ÷òî îí ìåíåå åôôåêòèâåí, ÷åì öèëîñòàçîë, â ïîñëåäíèõ ACCP ðåêîìåíäàöèÿõ îí íå ðåêîìåíäîâàí ïðè PAD (ïðè íàëè÷èè áîëåå äåéñòâåííîé àëüòåðíàòèâû), íî íå çíà÷èò, ÷òî îí íå åôôåêòèâåí...

Êîììåíòàðèè ê ñîîáùåíèþ:
Iluhin îäîáðèë(à):
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #120  
Ñòàðûé 01.10.2009, 22:24
Àâàòàð äëÿ Gilarov
Gilarov Gilarov âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,196
Ïîáëàãîäàðèëè 713 ðàç(à) çà 691 ñîîáùåíèé
Gilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Ðîìàí! ß íå îòðèöàþ òîãî, ÷òî PAD íåäîîöåíåí. ß äàæå íå ïðîòèâ àíãèîëîãèè - ïóñòü ðàáîòàþò. Íî, êàê ãîâîðèòñÿ, Âàì áû íàøè ïðîáëåìû... Ïîìíèòå, êàê â "Æóêå â ìóðàâåéíèêå"?
"Ó ìåíÿ â ýòî âðåìÿ áûëî âîññòàíèå â ïàíäåå! Ïåðâûé ìàññîâûé äåñàíò îêåàíñêîé èìïåðèè! Âû-òî äîëæíû ïîíèìàòü, ÷òî òàêîå... Ãîñïîäè! Äà åñëè ãîâîðèòü ÷åñòíî, ÿ î âàñ è äóìàòü òîãäà çàáûë!" Òàêèå ïèðîãè...
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 15:04.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.